Seeking Alpha

Janssen strikes licensing deal for investigational Alzheimer's treatment

  • Janssen Pharmaceuticals (JNJ +0.6%) inks a new development and commercialization deal with Finland's Orion Corp. for the latter's alpha-2c adrenoceptor antagonists including ORM-12741.
  • Orion gets a $31M upfront payment and is eligible for milestone payments and royalties — the company will use the upfront cash to help fund the Phase 2a study of ORM-12741.
  • ORM-12741 (which Janssen will have the right to commercialize outside of Europe) is being tested as a possible treatment for "the cognitive and behavioral symptoms related to Alzheimer's." (PR)
Comments (3)
  • Note that Janseen Pharma is NOT JNJ!!!!!
    JNJ=Johnson and Johnson.


    Stupid mistake. Don't be confused!
    20 Dec 2013, 03:27 PM Reply Like
  • What mistake are you referencing? Janssen Pharma is a subsidiary of JNJ. Ergo, no mistake was made.
    20 Dec 2013, 03:55 PM Reply Like
  • Please check it clearly says.
    22 Dec 2013, 12:47 PM Reply Like
DJIA (DIA) S&P 500 (SPY)